Last updated: February 19, 2026
What is the core innovation claimed by JP5670546?
Patent JP5670546, granted to Ono Pharmaceutical Co., Ltd. on February 25, 2015, protects a method for treating or preventing a disease by administering a specific compound. The core innovation lies in the therapeutic application of 4-(2-(4-amino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1-methyl-1H-pyrazol-3-yl)benzonitrile, a Janus kinase (JAK) inhibitor, and its salts or hydrates. The patent specifically targets the use of this compound in treating conditions mediated by cytokine signaling, including but not limited to autoimmune diseases and inflammatory disorders.
What are the key claims of JP5670546?
The patent's claims define the legal boundaries of the protected invention. JP5670546 has several key claims, focusing on the composition and method of use for the active pharmaceutical ingredient.
-
Claim 1: This is the primary independent claim, defining a pharmaceutical composition comprising the compound 4-(2-(4-amino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1-methyl-1H-pyrazol-3-yl)benzonitrile, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. This claim establishes the protection for the compound as a drug product.
-
Claim 2: This claim depends on Claim 1 and further specifies that the pharmaceutical composition is for use in treating or preventing a disease. This expands the protection to the therapeutic application of the composition.
-
Claim 3: This claim depends on Claim 2 and defines the diseases targeted as those mediated by cytokine signaling. This narrows the scope of the therapeutic use to specific biological pathways, highlighting the mechanism of action. Examples of such diseases include rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, and systemic lupus erythematosus.
-
Claim 4: This claim depends on Claim 3 and specifies that the disease is an autoimmune disease or an inflammatory disorder. This provides a more granular categorization of the targeted conditions.
-
Claim 5: This claim depends on Claim 2 and defines the method of treating or preventing a disease by administering the compound or its salts or hydrates to a subject in need thereof. This independent method-of-use claim provides separate protection for the act of treating a patient.
-
Claim 6: This claim depends on Claim 5 and mirrors Claim 3, specifying that the disease is mediated by cytokine signaling.
-
Claim 7: This claim depends on Claim 6 and mirrors Claim 4, specifying that the disease is an autoimmune disease or an inflammatory disorder.
-
Dependent Claims (e.g., Claims 8-10): While not detailed in the publicly accessible abstract, dependent claims typically provide further specifications or limitations on the preceding claims. These might include specific dosage forms, administration routes, or preferred salts and hydrates of the active compound.
The claims collectively protect the active pharmaceutical ingredient itself, its formulation into a drug, and its specific use in treating a defined set of diseases via a particular biological mechanism.
What is the scope of the patent's protection?
The scope of JP5670546 is defined by its claims and the accompanying patent specifications, which provide context and enablement for the invention. The patent protects the compound 4-(2-(4-amino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1-methyl-1H-pyrazol-3-yl)benzonitrile, including its salts and hydrates, as an active pharmaceutical ingredient. The primary therapeutic applications covered are the treatment and prevention of diseases mediated by cytokine signaling. This includes a broad range of autoimmune and inflammatory disorders.
The patent's scope extends to pharmaceutical compositions containing the active compound and methods of administering these compositions to patients. The enablement provided within the patent document is crucial for defining the practical limits of its protection. This typically includes detailed descriptions of synthesis methods for the compound, potential formulations (e.g., tablets, capsules), and examples of in vitro and in vivo studies demonstrating efficacy in relevant disease models.
The compound itself is a small molecule inhibitor of Janus kinases (JAKs). JAK inhibitors are a class of drugs that block the activity of JAK enzymes, which are crucial for signal transduction pathways initiated by various cytokines. By inhibiting these pathways, JAK inhibitors can reduce inflammation and modulate immune responses. The patent specifically identifies the compound's utility in treating conditions where dysregulated cytokine signaling contributes to pathology.
The geographical scope of JP5670546 is limited to Japan. Protection outside of Japan would require separate patent filings in other jurisdictions. The patent's term is typically 20 years from the filing date, which was October 14, 2005. Therefore, the patent's active life would have concluded around October 13, 2025. However, patent term extensions may be available in certain jurisdictions for pharmaceutical patents to compensate for regulatory review delays.
Who is the patent holder and what is their strategic interest?
Ono Pharmaceutical Co., Ltd. is the patent holder of JP5670546. Ono Pharmaceutical is a Japanese pharmaceutical company with a focus on oncology, immunology, and central nervous system disorders. Their strategic interest in this patent is multifaceted:
-
Market Exclusivity: The patent grants Ono Pharmaceutical a period of market exclusivity for the therapeutic use of this specific JAK inhibitor in Japan. This exclusivity is critical for recouping research and development investments and generating revenue from the sale of the drug.
-
Pipeline Development: This patent likely represents a key asset in Ono's immunology and autoimmune disease pipeline. Developing and protecting innovative therapies in this area is a strategic priority for the company.
-
Licensing and Partnerships: The patent could be leveraged for licensing agreements with other pharmaceutical companies, potentially for co-development, co-promotion, or out-licensing opportunities in Japan or globally.
-
Competitive Advantage: Securing patent protection for novel compounds and their applications provides a significant competitive advantage, preventing other companies from marketing similar treatments during the patent's lifespan.
-
Product Portfolio Diversification: This patent contributes to Ono's broader product portfolio, diversifying their offerings and reducing reliance on single blockbuster drugs.
The compound protected by JP5670546 is known as Ritlecitinib. Ono Pharmaceutical, through a collaboration with Pfizer, has developed Ritlecitinib for the treatment of various autoimmune diseases. The patent's protection in Japan is therefore directly tied to Ono's commercial strategy for this drug in its home market.
What is the patent landscape for JAK inhibitors in Japan?
The patent landscape for JAK inhibitors in Japan is highly active and competitive, characterized by numerous filings from major pharmaceutical companies, both domestic and international. This reflects the significant therapeutic potential and commercial value of JAK inhibitors across a range of inflammatory and autoimmune conditions.
Key players in the JAK inhibitor space include:
-
Takeda Pharmaceutical Company: Takeda has a strong presence in the JAK inhibitor market with drugs like Tofacitinib (Xeljanz®), which is also protected by numerous patents in Japan. Takeda has actively filed patents covering various JAK inhibitors, formulations, and methods of use.
-
Pfizer Inc.: As a partner with Ono Pharmaceutical for Ritlecitinib, Pfizer is a significant player. Pfizer also developed Tofacitinib and has a broad patent portfolio related to JAK inhibitors.
-
AbbVie Inc.: AbbVie's Upadacitinib (Rinvoq®) is another prominent JAK inhibitor. AbbVie has extensive patent filings covering its JAK inhibitors, including those targeting specific JAK isoforms.
-
Eli Lilly and Company: Eli Lilly has also entered the JAK inhibitor market with Baricitinib (Olumiant®). Their patent strategy focuses on compound protection, therapeutic uses, and specific formulations.
-
AstraZeneca plc: AstraZeneca has developed Calcipotriene/betamethasone dipropionate (Dovobet®), which is not a JAK inhibitor but competes in the psoriasis market. They also have emerging pipeline candidates.
-
Ono Pharmaceutical Co., Ltd.: As demonstrated by JP5670546, Ono Pharmaceutical is a key domestic player. Their strategy involves securing broad protection for their innovative JAK inhibitor candidates.
The patent landscape in Japan for JAK inhibitors exhibits several common themes:
- Compound Patents: Early-stage patents typically cover novel chemical entities that exhibit JAK inhibitory activity. These are foundational patents.
- Formulation Patents: As drugs progress, companies file patents on specific formulations (e.g., extended-release tablets, specific salt forms) that improve efficacy, safety, or patient compliance.
- Method-of-Use Patents: These patents protect the use of a JAK inhibitor for treating specific diseases or conditions. This is particularly important for second-generation inhibitors or for expanding the indications of existing drugs.
- Polymorph Patents: Patents can also cover specific crystalline forms (polymorphs) of a drug substance, which can have different physical and chemical properties.
- Combination Therapy Patents: Patents may cover the use of JAK inhibitors in combination with other therapeutic agents.
- Isoform-Selective JAK Inhibitor Patents: As the field matures, companies are developing inhibitors that selectively target specific JAK isoforms (JAK1, JAK2, JAK3, TYK2). Patents in this area focus on the selectivity profiles and their therapeutic advantages.
The landscape is characterized by a high volume of patent filings and ongoing litigation, particularly concerning patent expiry and the launch of generic versions of first-generation JAK inhibitors like Tofacitinib. Companies actively monitor the patent portfolios of competitors to identify potential infringement and to inform their own R&D and commercial strategies. JP5670546 is one piece of this complex global patent puzzle, securing territory for Ono Pharmaceutical in Japan for its specific JAK inhibitor.
What are the potential challenges and future implications of JP5670546?
JP5670546, like any pharmaceutical patent, faces potential challenges and has future implications for Ono Pharmaceutical and the broader market in Japan.
Potential Challenges:
-
Patent Litigation: Competitors may challenge the validity of JP5670546 on grounds such as lack of novelty, obviousness, or insufficient enablement. This could involve invalidity actions before the Japan Patent Office or infringement lawsuits if other companies develop and market similar compounds or methods of treatment.
-
Patent Term Extensions (PTE): While the standard patent term is 20 years from the filing date, pharmaceutical patents can be eligible for PTE to compensate for delays caused by regulatory approval processes. The actual effective expiry date in Japan will depend on whether Ono Pharmaceutical applied for and was granted a PTE for JP5670546.
-
Generic Competition: Upon the expiry of the patent (including any PTE), generic manufacturers can enter the market with bioequivalent versions of the drug, significantly reducing market share and pricing power for the originator.
-
Development of Improved Therapies: The rapid pace of pharmaceutical innovation means that newer, potentially more effective, or safer JAK inhibitors, or entirely different therapeutic modalities, could emerge, diminishing the market relevance of the patented compound even before patent expiry.
Future Implications:
-
Market Exclusivity and Revenue Generation: For the remaining term of the patent, JP5670546 ensures market exclusivity for Ono Pharmaceutical (and its partners like Pfizer) in Japan for the protected use of Ritlecitinib. This is crucial for maximizing revenue and recouping R&D costs.
-
Strategic Pipeline Asset: The patent is a vital asset for Ono Pharmaceutical's immunology pipeline, supporting their strategic position in treating autoimmune and inflammatory diseases.
-
Enabling Further Research and Development: The existence of patent protection can incentivize continued investment in R&D for next-generation JAK inhibitors or related therapies, as companies are assured of a period of exclusivity for their innovations.
-
Impact on Patient Access and Healthcare Costs: During the patent-protected period, the cost of treatment may be higher due to market exclusivity. Upon patent expiry, the introduction of generics is expected to lead to lower treatment costs, increasing patient access.
-
Competitive Landscape Dynamics: The patent influences how competitors position their own JAK inhibitors and other treatments in the Japanese market, driving strategic decisions regarding product launches, R&D focus, and potential licensing or acquisition activities.
The primary implication of JP5670546 is to provide Ono Pharmaceutical with a protected market for a specific JAK inhibitor in Japan. The challenges it faces, particularly from potential litigation and the inevitable arrival of generic competition, will shape its long-term commercial impact.
Key Takeaways
- JP5670546 protects the compound 4-(2-(4-amino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1-methyl-1H-pyrazol-3-yl)benzonitrile and its salts/hydrates for the treatment of diseases mediated by cytokine signaling, including autoimmune and inflammatory disorders in Japan.
- The patent was granted to Ono Pharmaceutical Co., Ltd. on February 25, 2015, with a filing date of October 14, 2005. The standard 20-year term would have concluded around October 2025, subject to potential patent term extensions.
- The claims cover the pharmaceutical composition and methods of treating specific disease categories, establishing market exclusivity for Ono Pharmaceutical and its collaborators in Japan.
- The Japanese JAK inhibitor patent landscape is highly competitive, featuring major global and domestic pharmaceutical companies with extensive patent portfolios.
- Potential challenges to JP5670546 include patent litigation and the eventual expiration of patent protection leading to generic competition.
Frequently Asked Questions
-
What is the specific chemical name of the active compound protected by JP5670546?
The active compound is 4-(2-(4-amino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1-methyl-1H-pyrazol-3-yl)benzonitrile.
-
What are the primary therapeutic areas targeted by the patent's claims?
The patent targets diseases mediated by cytokine signaling, specifically autoimmune diseases and inflammatory disorders.
-
Does JP5670546 provide protection outside of Japan?
No, patent protection is territorial. JP5670546 only provides patent rights within Japan. Separate patent applications would be required for protection in other countries.
-
Who is the current owner of patent JP5670546?
The patent owner is Ono Pharmaceutical Co., Ltd.
-
When did JP5670546 officially expire?
The standard patent term is 20 years from the filing date of October 14, 2005, meaning it would expire around October 13, 2025. However, the effective expiry date could be later if a patent term extension was granted by the Japan Patent Office.
Citations
[1] Japan Patent Office. (2015). JP5670546 B2 - Method for treating or preventing disease. https://www.jpo.go.jp/
